{"id":843,"date":"2024-04-30T13:01:16","date_gmt":"2024-04-30T05:01:16","guid":{"rendered":"https:\/\/zulcancerspecialist.com\/?page_id=843"},"modified":"2025-04-23T10:07:58","modified_gmt":"2025-04-23T02:07:58","slug":"areas-of-research","status":"publish","type":"page","link":"https:\/\/zulcancerspecialist.com\/?page_id=843","title":{"rendered":"Areas of Research"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"843\" class=\"elementor elementor-843\">\n\t\t\t\t<div class=\"elementor-element elementor-element-351979f e-flex e-con-boxed e-con e-parent\" data-id=\"351979f\" data-element_type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-c8dc357 e-con-full e-flex e-con e-child\" data-id=\"c8dc357\" data-element_type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-917946d elementor-widget elementor-widget-text-editor\" data-id=\"917946d\" data-element_type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h2 style=\"text-align: center;\"><span style=\"color: #4169e1;\">Areas of Research<\/span><\/h2><p>A phase III randomized study to determine whether bishosphonate treatment adds to the benefits of chemotherapy and\/or hormone therapy in the treatment of women with breast cancer (AZURE) &#8211; Sub-investigator<\/p><p>Program for the assessment of clinical cancer tests (PACCT-1) Trial Assigning Individualized Options for Treatment, the TAILORx Trial &#8211; Sub-investigator<\/p><p>A randomized, multi-centre, open label, phase III study of adjuvant lapatinib, transtuzumab, their sequence and their combination in patients with HER2\/ErbB2 positive primary breast cancer (ALLTO) \u2013 Sub-investigator<\/p><p>Axitinib (AG-013736) as second line therapy for metastatic renal cell cancer: AXIS Trial \u2013 Sub-investigator<\/p><p>A randomized, multi-centre, phase IIIb, open label, study of letrozole vs anastrozole in the adjuvant treatment of postmenopausal women with hormone receptor and node positive breast cancer (FACE) \u2013 Sub-investigator<\/p><p>A phase III adjuvant trial comparing three chemotherapy regimens in women with node-positive breast cancer: Docetaxel\/Doxorubicin\/Cyclophosphamide (TAC); Dose-dense (DD) Doxorubicin\/Cyclophosphamide followed by DD paclitaxel (DD AC\u2192P); DD AC followed by DD Paclitaxel plus Gemcitabine (DD AC\u2192PG); NSABP-B38 \u2013 Sub-investigator<\/p><p>A study of Pazopanib vs Sunitinib in the treatment of subjects with locally advanced and\/or metastatic renal cell carcinoma (COMPARZ) \u2013 sub-investigator<\/p><p>A randomized, double-blind, phase III trial comparing docetaxel combined with Dasatinib to Docetaxel combined with placebo in castration-resistant prostate cancer \u2013 Sub-investigator<\/p><p>EGF30008: A randomized, double-blind, placebo-controlled, multicentre phase III study comparing Lapatinib plus Letrozole in subjects with oestrogen\/progesterone receptor-positive advanced or metastatic breast cancer \u2013 Sub-investigator<\/p><p>A randomized, double-blind, placebo-controlled, multi-center, phase III study of Denosumab on prolonging bone metastases-free survival in men with hormone-refractory prostate cancer \u2013 Sub-investigator<\/p><p>A phase III, randomized, double blind, placebo controlled study of Abiraterone Acetate (CB7630) plus Prednisolone in patients with metastatic castration-resistant prostate cancer who failed Docetaxel-based chemotherapy (COUGAR) \u2013 Sub-investigator<\/p><p>A multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of\u00a0 AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy (SAVE-ONCO) &#8211;\u00a0 Sub-investigator<\/p><p>IBIS II trial; a randomized, double-blind control trial divided into 2 studies: The prevention study will compare Anastrozole vs placebo in a 2-arm design. The DCIS study will compare Tamoxifen vs Anastrozole in women with locally excised ductal carcinoma in situ (DCIS) \u2013 Sub-investigator<\/p><p>Detection of cardiac dysfunction in patients treated with Trastuzumab for HER-2 positive breast cancer (CADY) \u2013 Sub-investigator<\/p><p>A phase II study of the combination of Capecitabine and Lapatinib in patients with metastatic pancreatic cancer \u2013 Sub-investigator<\/p><p>Sunitinib treatment of renal adjuvant cancer (S-TRAC): A randomized, double-blind, phase III study of adjuvant Sunitinib vs placebo in subjects at high risk of recurrent RCC \u2013 Sub-investigator<\/p><p>NSABP-B42; A clinical trial to determine the efficacy of five years of Letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an Aromatase Inhibitor (AI) or Tamoxifen followed by an AI in prolonging disease-free survival in post-menopausal women with hormone receptor positive breast cancer \u2013 Sub-investigator<\/p><p>A multicenter, phase III, randomized trial of adjuvant therapy for patients with HER-2 positive, node-positive or high risk node-negative breast cancer comparing chemotherapy plusTrastuzumab with chemotherapy plus Trastuzumab plus Bevacizumab \u2013 Sub-investigator<\/p><p>A phase III, randomized trial of adjuvant chemotherapy with or without Bevacizumab for patients with completely resected stage IB (&gt;4cm) \u2013 IIA Non-Small Cell Lung Cancer \u2013 Sub-investigator<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Areas of Research A phase III randomized study to determine whether bishosphonate treatment adds to the benefits of chemotherapy and\/or [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"","ast-site-content-layout":"full-width-container","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-843","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/pages\/843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=843"}],"version-history":[{"count":13,"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/pages\/843\/revisions"}],"predecessor-version":[{"id":1191,"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=\/wp\/v2\/pages\/843\/revisions\/1191"}],"wp:attachment":[{"href":"https:\/\/zulcancerspecialist.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}